Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival: Potential for Intervention with 17-Allylamino Geldanamycin

Cancer Research

Volumn 64, Issue 1, 2004, Pages 286-291

  Nielsen, Torsten O ^b   Andrews, Heather N ^a   Cheang, Maggie ^b   Kucab, Jill E ^a   Hsu, Forrest D ^b   Ragaz, Joseph ^b   Gilks, C Blake ^b   Makretsov, Nikita ^b   Bajdik, Chris D ^b   Brookes, Christy ^a   Neckers, Leonard M ^c   Evdokimova, Valentina ^a   Huntsman, David G ^b   Dunn, Sandra E ^a,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

^d BC Research Institute of Women's and Children's Health   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GELDANAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; UROKINASE;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BENZOQUINONES; BREAST NEOPLASMS; DNA PRIMERS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LACTAMS, MACROCYCLIC; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, IGF TYPE 1; RIFABUTIN; RNA, MESSENGER; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 9144223655     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1242     Document Type: Article

References (30)

1. Guo, Y., Higazi, A. A. R., Arakelian, A., Sachais, B. R., Cines, D., Goldfarb, R. H., Jones, T. R., Kwaan, H., Mazar, A. P., and Rabbini, S. A. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J., 14: 1400-1410, 2000.
2. Guo, Y., Mazar, A. P., Lebrun, J. J., and Rabbani, S. A. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res., 62: 4678-4684, 2002.
3. Duffy, M. J., Maguire, T. M., McDermott, E. W., and O'Higgins, N. Urokinase plasminogen activator: a prognostic markers in multiple types of cancer. J. Surg. Oncol., 71: 130-135, 1999.
4. Look, M. P., van Putten, W. L., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S., Sweep, C. G., Ulm, K., Peyrat, J. P., Martin, P. M., Magdelenat, H., Brunner, N., Duggan, C., Lisboa, B. W., Bendahl, P. O., Quillien, V., Daver, A., Ricolleau, G., Meijer-van Gelder, M. E., Manders, P., Fiets, W. E., Blankenstein, M. A., Broet, P., Romain, S., Daxenbichler, G., Windbichler, G., Cufer, T., Borsmar, S., Kueng, W., Beex, L. V., Klijn, J. G., O'Higgins, N., Eppenberger, U., Janicke, F., Schmitt, M., and Foekens, J. A. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. (Bethesda), 94: 116-128, 2002.
5. Janicke, F., Schmitt, M., Ulm, K., Gossner, W., and Graeff, H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet, 28: 1049, 1989.
6. Muehlenweg, B., Sperl, S., Magdolen, V., Schmitt, M., and Harbeck, N. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. Expert Opin. Biol. Ther., 1: 683-691, 2001.
7. Webb, C. P., Hose, C. D., Koochekpour, S., Jeffers, M., Oskarsson, M., Sausville, E., Monks, A., and Vande Woude, G. F. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor Met: urokinase plasminogen activator-plasmin proteolytic network. Cancer Res., 60: 342-349 2000.
8. Egorin, M. J., Rosen, D. M., Wolff, J. H., Callery, P. S., Musser, S. M., and Eiseman, J. L. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res., 58: 2385-2396, 1998.
9. Kelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G., and Workman, P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino-17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. (Bethesda), 91: 1940-1949, 1999.
10. Basso, A. D., Solit, D. B., Munster, P. N., and Rosen, D. M. Ansamycin antibiotics inhibit AKT activation and cyclin D expression in breast cancer cells that overexpress Her2. Oncogene, 21: 1159-1166 2002.
11. Bagatell, R., Khan, O., Paine-Murrieta, G., Tayor, C. W., Akinaga S., and Whitsell, L. Destabilization of steroid receptors by heat shock protein 90 binding drugs: a ligand independent approach to hormonal therapy for breast cancer. Clin. Cancer Res., 7: 2076-2084, 2001.
12. Dunn, S. E., Torres, J. V., Nihei, N., and Barrett, J. C. The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: a new avenue for breast cancer therapy. Mol. Carcinog., 27: 10-17, 2000.
13. Dunn, S. E., Torres, J. V., and Barrett, J. C. Up-regulation of urokinase type plasminogen activator by insulin-like growth factor-1 depends upon phosphotidyl inositol-3 kinase and Map kinase kinase. Cancer Res., 61: 1367-1374, 2001.
14. Schulte, T. W., and Neckers, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biological activities with geldanamycin. Cancer Chemother. Pharmacol., 42: 273-279, 1998.
15. Torhorst, J., Bucher, C., Kononen, J., Haas, P., Zuber, M., Kochli, O. R., Moss, F., Dieterich, H., Moch, H., Mihatsch, M., Kallioniemi, O. P., and Sauter, G. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am. J. Pathol., 159: 2249-2256, 2001.
16. Zhang, D., Salto-Telez, M., Putti, T. C., Do, E., and Kaoy, E. S. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mol. Pathol., 16: 79-85 2003.
17. Hakam, A., Yeatman, T. J., Lu, L., Mora, L., Marcet, G., Nicosia, S. V., and Karl, D. Expression of insulin-like growth factor I receptor in colorectal cancer. Hum. Pathol., 30: 1128-1133 1999.
18. Hsu, F. D., Nielsen, T. O., Alkushi, A., Dupuis, B., Huntsman, D., Liu, C. L., van de Rijn, M., and Gilks, C. B. Multiple tumor tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod. Pathol., 15: 1374-1380 2002.
19. Dunn, S. E., Ehrlich, M., Sharp, N. J. H., Reiss, K., Solomon, G., Hawkins, R., Baserga, R., and Barrett, J. C. A dominant negative mutant of the insulin-like growth factor I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res., 58: 3353-3361, 1998.
20. Lawlor, E. R., Lim, J. F., Tao, W., Poremba, C., Chow, C. J., Kalousek, I. V., Kovar, H., MacDonald, T. J., and Sorensen, P. H. B. The Ewing tumor family of peripheral primitive neuroectodermal tumors expresses human gastrin-releasing peptide. Cancer Res., 58: 2469-2476 1998.
21. Zheng, F. F., Kuduk, S. D., Chiosis, G., Munster, P. N., Sepp-Lorenzino, L., Danishefsky, S. J., and Rosen, N. Identification of a geldanamycin dimer that induces the selective degradation of Her-family tyrosine kinases. Cancer Res., 60: 2090-2094, 2000.
22. Sepp-Lorenzino, L., Ma, Z., Lebwohl, D. E., Vinitsky, A., and Rosen, N. Herbimycin A induces the 20 S proteasome and ubiquitin dependent degradation of receptor tyrosine kinases. J. Biol. Chem., 270: 16580-16587, 1995.
23. Look, M. P., and Foekens, J. A. Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS, 107: 150-159, 1999.
24. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science (Wash. DC), 235: 177-182 1987.
25. Gum, R., Wang, S. W., Lengyel, E., Yu, D., Hung, M. C., Juarez, J., and Boyd, D. Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene. Anticancer Res., 15: 1167-1172, 1995.
26. Camp, R. L., Rimm, E. B., and Rimm, D. L. Met expression is associated with poor outcome in patients with axillary lymph node negative breast cancer. Cancer (Phila.), 86: 2259-2265, 1999.
27. Dunn, S. E., Hardman, R., Kari, F. W., and Barrett, J. C. Insulin-like growth factor 1 alters drug sensitivity of human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res., 57: 2687-2693, 1997.
28. Parisot, J. P., Hu, X. F., DeLuise, M., and Zalcberg, J. R. Altered expression of the IGF-I receptor in a tamoxifen-resistant human breast cancer cell line. Br. J. Cancer, 79: 693-700, 1999.
29. Lu, Y. Y., Zi, X., Zhao. Y., Mascarenhas, D., and Pollak, M. Insulin-like growth factor I receptor signaling and resistance to Trastuzumab (Herceptin). J. Natl. Cancer Inst. (Bethesda), 93: 1852-1857, 2001.
30. Soga, S., Sharma, S. V., Shiotsu, Y., Shimizu, M., Tahara, H., Yamaguchi, K., Ikuina, Y., Markata, C., Tamaoki, T., Kurebayasi, J., Schulte, T. W., Neckers, L. M., and Akinaga, S. Stereospecific antitumor activity of radicicol oxime derivatives. Cancer Chemother. Pharmacol., 48: 435-445, 2001.